Pembrolizumab plus Pharmacologic Ascorbate in the Treatment of Leiomyosarcoma.

ABSTRACT:

Introduction

Leiomyosarcoma (LMS) is a malignancy with smooth muscle differentiation. Metastatic LMS is associated with poor prognosis and limited efficacy of systemic treatment. Novel treatment modalities are desperately needed for this entity.

Case presentation

We report the first use of pembrolizumab plus pharmacologic ascorbate in 3 patients with metastatic LMS. All cases resulted in persistent objective responses and disease control significantly better than has been reported with chemotherapy or other immunotherapeutic approaches. Three patients with metastatic LMS, one each of uterine, vascular, and soft tissue origin, were treated with pembrolizumab plus pharmacologic ascorbate. The patient with uterine LMS received combination therapy at presentation and had persist

SUBMITTER: Rieth JM 

PROVIDER: S-EPMC11521403 | biostudies-literature | 2024 Jan-Dec

REPOSITORIES: biostudies-literature